tradingkey.logo

Biontech SE

BNTX
View Detailed Chart

104.150USD

+0.150+0.14%
Close 04/30, 16:00ETQuotes delayed by 15 min
24.99BMarket Cap
LossP/E TTM

Biontech SE

104.150

+0.150+0.14%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.14%

5 Days

-9.30%

1 Month

-13.22%

6 Months

-7.91%

Year to Date

-8.60%

1 Year

+17.26%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 21 analysts
BUY
Current Rating
137.105
Target Price
31.83%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Biontech SE
BNTX
21
CRISPR Therapeutics AG
CRSP
29
Regeneron Pharmaceuticals Inc
REGN
28
Intellia Therapeutics Inc
NTLA
28
Exact Sciences Corp
EXAS
27
Moderna Inc
MRNA
27
1
2
3
...
112

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(7)
Neutral(3)
Buy(2)
Indicators
Sell(2)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
3.005
Neutral
RSI(14)
48.950
Neutral
STOCH(KDJ)(9,3,3)
45.262
Sell
ATR(14)
7.693
Low Volatility
CCI(14)
33.940
Neutral
Williams %R
44.883
Buy
TRIX(12,20)
-0.173
Sell
StochRSI(14)
9.197
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
109.078
Sell
MA10
104.789
Sell
MA20
98.558
Buy
MA50
110.492
Sell
MA100
111.998
Sell
MA200
104.181
Sell

News

More news coming soon, stay tuned...

Company

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company codeBNTX
CompanyBiontech SE
CEOProf. Ugur Sahin, M.D.
Websitehttps://www.biontech.com/